Harbour Investments’s BioCryst Pharmaceuticals BCRX Stock Holding History

Harbour Investments’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$520	Hold	52	–	–	﹤0.01%	4365
2026 Q1	$495	Buy	52 +1	+2%	+$8	﹤0.01%	4261
2025 Q4	$398	Hold	51	–	–	﹤0.01%	3585
2025 Q3	$387	Hold	51	–	–	﹤0.01%	3546
2025 Q2	$457	Hold	51	–	–	﹤0.01%	3389
2025 Q1	$383	Hold	51	–	–	﹤0.01%	3368
2024 Q4	$384	Hold	51	–	–	﹤0.01%	3306
2024 Q3	$388	Hold	51	–	–	﹤0.01%	3219
2024 Q2	$315	Hold	51	–	–	﹤0.01%	3132
2024 Q1	$259	Hold	51	–	–	﹤0.01%	3092
2023 Q4	$305	Hold	51	–	–	﹤0.01%	2989
2023 Q3	$361	Hold	51	–	–	﹤0.01%	2835
2023 Q2	$359	Hold	51	–	–	﹤0.01%	2849
2023 Q1	$425	Hold	51	–	–	﹤0.01%	2825
2022 Q4	$585	Hold	51	–	–	﹤0.01%	2778
2022 Q3	$1K	Hold	51	–	–	﹤0.01%	2540
2022 Q2	$1K	Buy	+51	New	+$526	﹤0.01%	2540
2021 Q4	–	Sell	-7	Closed	–	–	2707
2021 Q3	$0	Buy	7 +2	+40%	+$32	﹤0.01%	3731
2021 Q2	$0	Hold	5	–	–	﹤0.01%	3767
2021 Q1	$0	Buy	+5	New	+$52	﹤0.01%	3595

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Harbour Investments's BCRX Position: Q2 2026 in Review

Harbour Investments held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 52 shares worth $520. The position accounts for ﹤0.01% of the portfolio, ranked #4365.

Harbour Investments first reported a position in BCRX in Q1 2021 and has held it in 20 quarters since. The position peaked at $1K in Q3 2022. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Harbour Investments held 52 shares of BioCryst Pharmaceuticals worth $520 as of Q2 2026.
Harbour Investments left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
BioCryst Pharmaceuticals made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #4365 holding.
Harbour Investments first reported a position in BioCryst Pharmaceuticals in Q1 2021 and has held it in 20 quarters since.
Harbour Investments's BioCryst Pharmaceuticals position peaked at $1K in Q3 2022.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.